NovaBridge Biosciences (NBP) Liabilities from Discontinued Operations (2023)
NovaBridge Biosciences (NBP) posted quarterly Liabilities from Discontinued Operations of 8318000.0 for Q4 2023, down 92.98% year-over-year from 118555000.0 in Q4 2022, and down 92.98% quarter-over-quarter from 118555000.0 in Q4 2022.
Powered by 
Analysis
NovaBridge Biosciences (NBP) Liabilities from Discontinued Operations (2023) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Liabilities from Discontinued Operations for 2 consecutive years, with 8318000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Liabilities from Discontinued Operations fell 92.98% year-over-year to 8318000.0; the TTM figure through Dec 2023 stood at 8318000.0 (down 92.98% YoY), while the FY2023 annual figure was 49669000.0, down 58.1% from the prior year.
- Liabilities from Discontinued Operations fell to 8318000.0 in Q4 2023 per NBP's latest filing, from 118555000.0 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 118555000.0 in Q4 2022 and bottomed at 8318000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | NovaBridge Biosciences | 199.33 Mn | 199.33 Mn | - |